Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:LGND NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$8.41-0.7%$9.03$6.00▼$11.23$2.15B0.574.65 million shs2.50 million shsCLDXCelldex Therapeutics$28.62-4.4%$32.00$19.52▼$35.79$2.35B0.95721,094 shs1.27 million shsLGNDLigand Pharmaceuticals$237.00+0.5%$220.63$103.43▼$247.38$4.73B1.17184,397 shs174,943 shsMNKDMannKind$3.40-3.4%$2.98$2.23▼$6.51$1.09B1.135.68 million shs3.24 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+2.95%-6.67%-5.95%+0.15%-23.07%CLDXCelldex Therapeutics+0.62%-5.58%-11.61%+1.70%+52.16%LGNDLigand Pharmaceuticals+0.64%+0.53%+1.55%+16.84%+127.27%MNKDMannKind+4.76%-3.30%+23.08%+34.87%-19.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$8.41-0.7%$9.03$6.00▼$11.23$2.15B0.574.65 million shs2.50 million shsCLDXCelldex Therapeutics$28.62-4.4%$32.00$19.52▼$35.79$2.35B0.95721,094 shs1.27 million shsLGNDLigand Pharmaceuticals$237.00+0.5%$220.63$103.43▼$247.38$4.73B1.17184,397 shs174,943 shsMNKDMannKind$3.40-3.4%$2.98$2.23▼$6.51$1.09B1.135.68 million shs3.24 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+2.95%-6.67%-5.95%+0.15%-23.07%CLDXCelldex Therapeutics+0.62%-5.58%-11.61%+1.70%+52.16%LGNDLigand Pharmaceuticals+0.64%+0.53%+1.55%+16.84%+127.27%MNKDMannKind+4.76%-3.30%+23.08%+34.87%-19.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$20.70146.14% UpsideCLDXCelldex Therapeutics 2.80Moderate Buy$49.7873.93% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$257.718.74% UpsideMNKDMannKind 2.60Moderate Buy$8.97163.79% UpsideCurrent Analyst Ratings BreakdownLatest MNKD, LGND, CLDX, and BCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026BCRXBioCryst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/1/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$11.005/15/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/13/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $54.005/8/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $48.005/8/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$252.00 ➝ $262.005/7/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $10.005/7/2026MNKDMannKind HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.005/7/2026BCRXBioCryst Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$25.00 ➝ $28.005/7/2026BCRXBioCryst Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$22.00 ➝ $21.005/7/2026MNKDMannKind Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$3.50 ➝ $4.75(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.44$1.23 per share6.84($0.57) per share-14.75CLDXCelldex Therapeutics$1.54M1,458.69N/AN/A$7.93 per share3.61LGNDLigand Pharmaceuticals$268.09M17.72$7.89 per share30.04$51.68 per share4.59MNKDMannKind$348.97M3.01$0.06 per share56.89($0.17) per share-20.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A26.28N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)LGNDLigand Pharmaceuticals$124.45M$7.3732.1630.352.5155.95%16.19%11.13%8/6/2026 (Estimated)MNKDMannKind$5.86M-$0.07N/A28.33N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)Latest MNKD, LGND, CLDX, and BCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million5/6/2026Q1 2026MNKDMannKind-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92LGNDLigand Pharmaceuticals0.4521.2820.95MNKDMannKindN/A1.871.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals3.80%CLDXCelldex Therapeutics5.20%LGNDLigand Pharmaceuticals7.00%MNKDMannKind2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableMNKDMannKind400308.95 million300.92 millionOptionableMNKD, LGND, CLDX, and BCRX HeadlinesRecent News About These CompaniesMannKind Corporation Presents New Clinical Data Supporting Afrezza and FUROSCIX at ADA 2026 Scientific Sessions2 hours ago | quiverquant.comQData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems2 hours ago | globenewswire.comMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib ...June 3 at 1:44 PM | finance.yahoo.comMannKind Corporation Advances Nintedanib DPI Program for IPF with Phase 1b INFLO-1 Study Data Expected in Q3 2026June 3 at 6:31 AM | quiverquant.comQMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPFJune 3 at 6:05 AM | globenewswire.comMannKind At An Inflection Point: Pediatric Expansion Drives The StoryJune 2 at 10:51 PM | seekingalpha.comMannKind Gains FDA Approval for Afrezza Pediatric UseJune 2 at 8:50 AM | tipranks.comMannKind (NASDAQ:MNKD) Trading Down 8.1% - Time to Sell?June 1, 2026 | marketbeat.comMannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes MarketMay 30, 2026 | marketbeat.comOn Friday, the FDA expanded its approved use of Afrezza for kids six years and olderMay 30, 2026 | msn.comMannKind Gets FDA Approval for Diabetes Drug for Kids and TeensMay 30, 2026 | marketwatch.comError: Response status code does not indicate success: 503 (Service Unavailable).May 30, 2026 | americanbankingnews.comMannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older TranscriptMay 29, 2026 | seekingalpha.comMannKind to Host Conference Call Today to Discuss Afrezza Pediatric ApprovalMay 29, 2026 | globenewswire.comMannKind Corporation Announces FDA Approval of Afrezza® Inhalation Powder for Pediatric Use in Type 1 and Type 2 DiabetesMay 29, 2026 | quiverquant.comQUS FDA approves MannKind's inhaled insulin for childrenMay 29, 2026 | reuters.comMannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with DiabetesMay 29, 2026 | globenewswire.comMNKD stock eyes best month since 2022 ahead of FDA decision on pediatric diabetes treatmentMay 29, 2026 | msn.comMannKind Released From Major Afrezza Trial ObligationMay 28, 2026 | tipranks.comMannKind to Present at Jefferies Global Healthcare ConferenceMay 27, 2026 | globenewswire.comMannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) SystemsMay 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNKD, LGND, CLDX, and BCRX Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$8.41 -0.06 (-0.71%) Closing price 04:00 PM EasternExtended Trading$8.28 -0.13 (-1.59%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$28.62 -1.31 (-4.38%) Closing price 04:00 PM EasternExtended Trading$28.56 -0.06 (-0.21%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$237.00 +1.09 (+0.46%) Closing price 04:00 PM EasternExtended Trading$237.25 +0.25 (+0.11%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.MannKind NASDAQ:MNKD$3.40 -0.12 (-3.41%) Closing price 04:00 PM EasternExtended Trading$3.45 +0.05 (+1.44%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
